

Pembrolizumab: The Evolving Standard of Care in Advanced and Early-Stage Lung Cancer

Monday, 24 September 2018

12:00 – 13:30

Merck & Co., Inc.
Supported Symposium

Metro Toronto Convention Centre
Plenary Hall – Exhibition Hall A,
Level 300, MTCC North Building
Toronto, Canada

Chair: Quincy Chu (Canada)

CHAIR

Quincy Chu

Associate Professor
Department of Oncology
University of Alberta
Cross Cancer Institute
Edmonton, Canada

FACULTY

Joachim Aerts

Professor
Erasmus University Medical Center
Rotterdam, Netherlands

Silvia Novello

Professor of Medical Oncology
Department of Oncology
AOU San Luigi
University of Turin
Orbassano, Italy

Martin Reck

Head, Department of Thoracic Oncology
Lung Clinic Grosshansdorf
Grosshansdorf, Germany

This program was approved by the IASLC 19th World Conference on Lung Cancer Program Committee as an independent activity held in conjunction with the IASLC 19th World Conference on Lung Cancer. This program is not sponsored or endorsed by IASLC.

Educational Objectives

- Review the current immune checkpoint inhibitor monotherapy treatment landscape for patients with advanced NSCLC
- Gain an understanding of the rationale for combination therapy and the future of combination strategies in the treatment of patients with lung cancer
- Consider the potential for use of these agents and treatment strategies in early-stage NSCLC

AGENDA

| | | |
|---------------|---|----------------|
| 12:00 | Welcome and Introduction | Quincy Chu |
| 12:00 – 12:15 | First- and Second-Line Use of Immune Checkpoint Inhibitor Monotherapy for Metastatic NSCLC | Martin Reck |
| 12:15 – 12:30 | Combination Options in First-Line Metastatic NSCLC | Silvia Novello |
| 12:30 – 12:45 | Future Utilization of Immunotherapy | Quincy Chu |
| 12:45 – 13:00 | Patient Selection – Cases on the Use of Monotherapy, Chemotherapy/IO Combinations, and IO/IO Combinations | Joachim Aerts |
| 13:00 – 13:25 | Panel Discussion | All |
| 13:25 – 13:30 | Closing Remarks | Quincy Chu |